AI Engines For more Details: Perplexity Kagi Labs You
Diagnostic Imaging Enhancement: Iocetamic acid is administered orally or intravenously to improve the visibility of the bile ducts and gallbladder during radiographic examinations. It provides contrast enhancement, allowing healthcare providers to visualize these structures more clearly and detect abnormalities such as gallstones, tumors, or bile duct obstructions.
Adverse Reactions: Like other iodinated contrast agents, iocetamic acid can cause adverse reactions in some individuals. Common side effects may include:
Allergic Reactions: Allergic reactions to iocetamic acid are possible but uncommon. Some individuals may experience mild allergic symptoms such as rash, itching, or swelling. In rare cases, severe allergic reactions such as anaphylaxis may occur, which can be life-threatening and require immediate medical attention.
Renal Effects: Iocetamic acid, like other iodinated contrast agents, can potentially cause kidney damage, especially in patients with pre-existing renal impairment or other risk factors. This adverse effect is known as contrast-induced nephropathy (CIN) and is characterized by a temporary decrease in kidney function following contrast exposure. Patients with impaired renal function should be closely monitored, and precautions may be taken to minimize the risk of CIN.
Thyroid Effects: Iocetamic acid contains iodine, which can affect thyroid function. Patients with thyroid disorders or those at risk of iodine-induced thyroid dysfunction should be monitored carefully.
Precautions: Healthcare providers should assess patients for any history of allergies, asthma, kidney disease, or thyroid disorders before administering iocetamic acid. Special precautions may be necessary for vulnerable populations, such as pregnant or breastfeeding women and pediatric patients.
Contrast Extravasation: In rare cases, iocetamic acid may extravasate (leak) from the injection site into surrounding tissues, leading to tissue irritation or damage. Prompt recognition and management of extravasation events are essential to minimize potential complications.
Contraindications: Iocetamic acid is contraindicated in patients with a known hypersensitivity to iodinated contrast agents and in those with severe renal impairment, unless the benefits outweigh the risks.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.6 | 1 | -0.67 |
| ADHD | 4.8 | 0.9 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2.3 | 0.35 |
| Allergies | 6.6 | 3.8 | 0.74 |
| Allergy to milk products | 2.1 | 1.6 | 0.31 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 5.8 | 6.7 | -0.16 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 1 | 2.4 |
| Ankylosing spondylitis | 4 | 1.4 | 1.86 |
| Anorexia Nervosa | 1.6 | 2.7 | -0.69 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 5.4 | 3 | 0.8 |
| Atherosclerosis | 1.8 | 1.6 | 0.13 |
| Atrial fibrillation | 3.5 | 2.3 | 0.52 |
| Autism | 9.1 | 8.8 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 3.3 | -2.67 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 1.5 | 4 | -1.67 |
| Cerebral Palsy | 1.6 | 1.3 | 0.23 |
| Chronic Fatigue Syndrome | 4.7 | 5.2 | -0.11 |
| Chronic Kidney Disease | 4.9 | 2.8 | 0.75 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 2 | -0.11 |
| Chronic Urticaria (Hives) | 1.6 | 0.8 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 7 | 2.2 | 2.18 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 2.3 | 2 | 0.15 |
| COVID-19 | 9.5 | 11 | -0.16 |
| Crohn's Disease | 7.1 | 5.5 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1.9 | -1.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 2.9 | 1.4 | 1.07 |
| Denture Wearers Oral Shifts | 1.8 | 1.8 | |
| Depression | 10 | 9.2 | 0.09 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.9 | 1.8 | 0.06 |
| Endometriosis | 3.2 | 2.3 | 0.39 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 1.9 | 0.74 |
| erectile dysfunction | 1.9 | 0.3 | 5.33 |
| Fibromyalgia | 2.8 | 1.2 | 1.33 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 4.1 | 0.17 |
| gallstone disease (gsd) | 3.1 | 1.4 | 1.21 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 2.9 | 2.7 | 0.07 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 1 | 1.3 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.7 | 0.3 | 4.67 |
| Hashimoto's thyroiditis | 3.7 | 2.1 | 0.76 |
| Heart Failure | 4.6 | 1.7 | 1.71 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.6 | 0.6 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.5 | 0.6 |
| hyperglycemia | 2.5 | 1.8 | 0.39 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.9 | 5.9 | -0.2 |
| Hypothyroidism | 0.2 | 1 | -4 |
| Hypoxia | 3.5 | 0.6 | 4.83 |
| IgA nephropathy (IgAN) | 1.9 | 4.2 | -1.21 |
| Inflammatory Bowel Disease | 8.9 | 8.9 | 0 |
| Insomnia | 2.3 | 3.1 | -0.35 |
| Intelligence | 1 | 0.3 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.3 | 4.8 | 0.73 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 7.8 | 5.2 | 0.5 |
| Long COVID | 6.2 | 8.9 | -0.44 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.5 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.4 | 0.9 | 0.56 |
| ME/CFS with IBS | 0.5 | 2 | -3 |
| ME/CFS without IBS | 1.6 | 1.9 | -0.19 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.8 | 1.63 |
| Metabolic Syndrome | 7.9 | 7.4 | 0.07 |
| Mood Disorders | 10.8 | 7.7 | 0.4 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 7.2 | 5.2 | 0.38 |
| Multiple system atrophy (MSA) | 1.3 | 0.7 | 0.86 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.4 | -10.33 |
| Neuropathy (all types) | 0.9 | 2.8 | -2.11 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.5 | 5.1 | 0.08 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 11.5 | 9 | 0.28 |
| obsessive-compulsive disorder | 4.8 | 4.1 | 0.17 |
| Osteoarthritis | 2.1 | 1.4 | 0.5 |
| Osteoporosis | 2.5 | 1.8 | 0.39 |
| pancreatic cancer | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 9.1 | 5.5 | 0.65 |
| Polycystic ovary syndrome | 5.3 | 3.4 | 0.56 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.4 | 2.4 | 0 |
| Psoriasis | 3.2 | 2.6 | 0.23 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.5 | 3.7 | 1.3 |
| Rosacea | 1.3 | 1 | 0.3 |
| Schizophrenia | 7.1 | 3.3 | 1.15 |
| scoliosis | 0.6 | 1.2 | -1 |
| Sjögren syndrome | 2.9 | 2.6 | 0.12 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.6 | 2.17 |
| Stress / posttraumatic stress disorder | 3.1 | 3.2 | -0.03 |
| Systemic Lupus Erythematosus | 4 | 1.9 | 1.11 |
| Tic Disorder | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 3.8 | 3.8 | 0 |
| Type 2 Diabetes | 7.5 | 7 | 0.07 |
| Ulcerative colitis | 5.1 | 6.3 | -0.24 |
| Unhealthy Ageing | 4.7 | 2.2 | 1.14 |
| Vitiligo | 1.9 | 1.3 | 0.46 |
